Change of Venue for General Meeting-17 Feb 2020

RNS Number : 6842C

ValiRx PLC

12 February 2020

 

ValiRx Plc

("ValiRx" or the "Company")

CHANGE OF VENUE FOR GENERAL MEETING - 17 FEBRUARY 2020

London, UK, 12 February 2020: ValiRx Plc (AIM: VAL), a clinical stage biotechnology company, announces that due to flooding at the venue proposed for the General Meeting convened for 9:00 a.m. on 17 February 2020, the Company has changed the location of the General Meeting from 180-186 Kings Cross Road, London, WC1X 9DE ("Original Venue") to the offices of Allenby Capital Limited, 5 St. Helen's Place, London, EC3A 6AB ("New Venue").

The General Meeting will commence at 9:00 a.m. on 17 February 2020 at the Original Venue for the sole purpose of immediately adjourning it to 9:45 a.m. at the New Venue.

Shareholders should therefore make their way directly to the New Venue for 9:45 a.m. on 17 February 2020 at which time the business of the General Meeting will be conducted.  Any shareholders who arrive at the Original Venue at 9:00 a.m. will be invited to go to the New Venue.

The business to be conducted at the General Meeting remains as set out in the Notice of General Meeting and no other changes to the procedures for voting at and attending the General Meeting are proposed.  There will be no effect on voting instructions already given by way of proxy card or through or other intermediaries, which will remain valid.

For more information, please contact:

ValiRx plc	Tel: [phone] www.valirx.com
Dr Satu Vainikka, Chief Executive	Tel: [phone]
Tarquin Edwards, Head of Communications.	Tel: [phone] [e-mail]
Cairn Financial Advisers LLP (Nominated Adviser) Liam Murray / Jo Turner / Ludovico Lazzaretti	Tel: [phone]
Allenby Capital Limited (Joint Broker) Jeremy Porter / Alex Brearley (Corporate Finance) Kelly Gardiner (Equity Sales)	Tel: [phone]
ETX Capital Limited (Joint Broker) Thomas Smith	Tel: [phone]

Notes for Editors

About ValiRx

ValiRx is a biotechnology oncology focused company specialising in developing novel treatments for cancer and associated biomarkers. It aims to make a significant contribution in "precision" medicine and science, namely to engineer a breakthrough into human health and well-being, through the early detection of cancer and its therapeutic intervention.

The Company's business model focuses on out-licensing therapeutic candidates early in the development process. By aiming for early-stage value creation, the company reduces risk considerably while increasing the potential for realising value. The group is already in licensing discussions with major players in the oncology field.

ValiRx's two classes of drugs in development, which each have the potential for meeting hitherto unmet medical needs by existing methods, have worldwide patent filings and agreed commercial rights.   They originate or derive from World class institutions, such as Cancer Research UK and Imperial College. 

Until recently, cancer treatments relied on non-specific agents, such as chemotherapy.  With the development of target-based agents, primed to attack cancer cells only, less toxic and more effective treatments are now possible. New drugs in this group-such as those in ValiRx's pipeline-promise to greatly improve outcomes for cancer patients.

The Company listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.

 

END

 

 

MSCZZGMZNMMGGZM